No approved hantavirus vaccine exists as of May 2026, driving the 89.5% market-implied probability against availability by year-end. Most candidates remain in preclinical testing or early Phase 1 trials, with DNA and mRNA platforms showing neutralizing antibody responses in small human studies and animal models but requiring multiple doses and facing major regulatory and manufacturing hurdles. The recent Andes virus outbreak linked to eight confirmed or suspected cases has accelerated some preclinical work, yet experts note that standard timelines for completing Phase 2/3 efficacy trials and securing licensure typically exceed five years absent unprecedented funding. Sporadic case patterns and limited commercial incentives further constrain rapid progress, consistent with historical vaccine development benchmarks for similar rodent-borne pathogens.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$89,055 交易量
$89,055 交易量
2026-12-31
$89,055 交易量
$89,055 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists as of May 2026, driving the 89.5% market-implied probability against availability by year-end. Most candidates remain in preclinical testing or early Phase 1 trials, with DNA and mRNA platforms showing neutralizing antibody responses in small human studies and animal models but requiring multiple doses and facing major regulatory and manufacturing hurdles. The recent Andes virus outbreak linked to eight confirmed or suspected cases has accelerated some preclinical work, yet experts note that standard timelines for completing Phase 2/3 efficacy trials and securing licensure typically exceed five years absent unprecedented funding. Sporadic case patterns and limited commercial incentives further constrain rapid progress, consistent with historical vaccine development benchmarks for similar rodent-borne pathogens.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市场开放时间： May 4, 2026, 10:39 AM ET
交易量
$89,055结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists as of May 2026, driving the 89.5% market-implied probability against availability by year-end. Most candidates remain in preclinical testing or early Phase 1 trials, with DNA and mRNA platforms showing neutralizing antibody responses in small human studies and animal models but requiring multiple doses and facing major regulatory and manufacturing hurdles. The recent Andes virus outbreak linked to eight confirmed or suspected cases has accelerated some preclinical work, yet experts note that standard timelines for completing Phase 2/3 efficacy trials and securing licensure typically exceed five years absent unprecedented funding. Sporadic case patterns and limited commercial incentives further constrain rapid progress, consistent with historical vaccine development benchmarks for similar rodent-borne pathogens.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$89,055结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No approved hantavirus vaccine exists as of May 2026, driving the 89.5% market-implied probability against availability by year-end. Most candidates remain in preclinical testing or early Phase 1 trials, with DNA and mRNA platforms showing neutralizing antibody responses in small human studies and animal models but requiring multiple doses and facing major regulatory and manufacturing hurdles. The recent Andes virus outbreak linked to eight confirmed or suspected cases has accelerated some preclinical work, yet experts note that standard timelines for completing Phase 2/3 efficacy trials and securing licensure typically exceed five years absent unprecedented funding. Sporadic case patterns and limited commercial incentives further constrain rapid progress, consistent with historical vaccine development benchmarks for similar rodent-borne pathogens.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题